EXAGEN INC.
Close on Oct 19, 2026
- Market cap
- $179.54M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | Before market open | $17.30M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 29, 2025 | Before market open | $17.20M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | $12.50M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue guidance | full-year 2026 | $72.00M to $75.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Exagen filed with the SEC
Exagen Inc. Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Reports First Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Announces Select Preliminary 2025 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Exagen Inc. Reports Strong Q3 2025 Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Reports Strong Q2 2025 Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Appoints Chas McKhann to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of
Other events · EX-99.1 to Form 8-K
Exagen Inc. Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Exagen Inc. Prices Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Exagen Inc. Reports Third Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Reports Strong Second Quarter 2024 Results:
Results of operations · EX-99.1 to Form 8-K
Exagen Appoints Jeffrey G. Black as New Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Exagen Inc. Reports Strong First Quarter 2024 Results:
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Announces Changes to the Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Reports Strong Third Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Reports Strong Second Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Appoints Paul Kim to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Exagen Inc. Reports First Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Exagen Inc. Reports Third Quarter 2022 Results
Results of operations · Prior financials no longer reliable · EX-99.1 to Form 8-K
Exagen Announces Appointment of John Aballi as CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Exagen Inc. Reports Second Quarter 2022 Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Reports First Quarter 2022 Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
Results of operations · EX-99.1 to Form 8-K
EXAGEN CONFIDENTIAL1 Rheumatoid Arthritis Drug Response
Regulation FD disclosure · EX-99.1 to Form 8-K
Exagen Inc. Reports Third Quarter 2021 Results
Results of operations · EX-99.1 to Form 8-K
Exagen Inc. Announces $27.2 Million Debt Refinancing
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K